 | ||
 |
 |
 |
 | ||
 | ||
Exhibitor profiles and offers |
 |
Name of company / organization:Joint Stock Company "Farmak"Name of principle person or persons attending the exhibition / conferenceOleg Siarkevych, Export and Foreign Markets Development Director Oleg Siarkevych has graduated from Lviv Medical University with Master of Science degree in pharmacy in 1985. In 1992 he has completed his post-graduate study at Kharkiv Medical University and defended Ph.D in Pharmacy. In 1997 Oleg Siarkevych has finished joint program of Lviv Institute of Management and Wayne State University School of Business Administration (USA) and was awarded Master of Business Administration degree. Since 1999 he was appointed Director General of JSC "Galychfarm" and in 2000 he became Marketing Director of JSC "Farmak". Since 2003 He is working on the position of Export and Foreign Markets Development Director of JSC "Farmak". Type of business in which you are involvedJSC "Farmak" is one of the leading Ukrainian pharmaceutical manufacturers that occupies a third place in rating of national pharmaceutical companies and provides almost 12% of the total internal output of Ukrainian pharmaceutical industry. JSC "Farmak" was created on the platform of the Lomonosov Chemical-Pharmaceutical Plant founded in 1925. The company shifted from the production of raw materials (active pharmaceutical ingredients) to the manufacturing of the finished pharmaceuticals.Presently JSC "Farmak" has more than 1000 employees, annual sales comprising up to 40 million USD; over 20% of products are exported. The company was certified according to ISO 9001:2000. JSC Farmak has six main production lines and units:
Specific offer to American companiesJSC "Farmak" is interested in establishing cooperation, partnership and business relations in following activities:
Export of our products in finished dosage forms and in bulk
Co-marketing and transfer of technologies
Contract-manufacturing
R&D cooperation
Brief description of original products: AMIZON 0,25g tablets INN: AMIZON, ATC: L03AX12 CHEMICAL NAME: N-methyl-4-benzylcarbamidopyridinium iodide PHARMACOLOGICAL GROUP: Cytokines and immunomodulators Pharmacological properties: Amizon possesses immunomodulating activity by strengthening humoral (increase of the titer of antibodies and endogenic interferon in the blood plasma in 3-4 times) and cellular (stimulation of functional activity of T-lymphocytes and macrophages) components of immunity, and also by influencing on the factors of a natural antibacterial resistance (at the level of a lysozyme). Besides, Amizon has marked analgesic and anti-inflammatory effect. The analgesic effect of Amizon is attained through a reticular formation of a brainstem. The antipyretic properties of Amizon are due to its influence on thermoregulatory centers of the intermediate brain. Anti-inflammatory effect is a result of the stabilization of cellular and lysosomal membranes, inhibition of basophil degranulation, antioxidant action, normalization of the level of prostaglandins, cyclical nucleotides and energy metabolism in the inflammatory lesion, and also reduction of vascular reactions. Amizon has no hemo- and nephrotoxic properties, it does not render negative influence on a blood count, hemopoiesis and mucosa of a gastrointestinal tract. The drug has no local irritating, allergenic properties, embryotoxic, mutagen and teratogenic effect. ANTRAL, tab. 0,2 No.30 INN: ANTRAL, ATC: A05B A08 CHEMICAL NAME. Tris-[N(2,3-dimethylphenyl) anthranilato]aluminium PHARMACOLOGICAL GROUP. Liver therapy Pharmacological properties: Antral belongs to the group of hepatoprotectors. It is effective in the treatment of acute or chronic hepatitis of different origin, liver cirrhosis, reduces asthenovegetative disorders, increases appetite, improves sleep, reduces dyspeptic phenomena. During course of treatment the drug normalizes the levels of a bilirubin, gamma globulins, cholesterol in blood, prothrombin index, activity of transaminases and alkaline phosphatase. Antral has prolonged anti-inflammatory, analgesic, antipyretic activity, as well as immunomodulating properties and antiviral activity in relation to hepatitis viruses A, E and B. Results of preclinical trials have shown, that Antral, under the conditions of acute, subacute and chronic liver damage by different xenobiotics and their combinations decreases severity of consequences of the action of hepatic toxins, activates reparative processes in hepatocytes, normalizes indicators of structural and functional condition of a liver in adult, young and juvenile animals. The drug inhibits lipid peroxidation in blood and tissues, supports an activity of antioxidant systems of an organism, promotes stabilization of a liver structures and membranes of hepatocytes. Antral has no negative influence on functions of organs and systems of an organism, no cumulative properties, as well as no immunotoxic, local allergenic, ulcerogenic, embryotoxic and teratogenic effect. ISODIBUT, tab. 0,5 No.30 INN: ISODIBUTUM, ATC: A10X A02 CHEMICAL NAME: 1,3-Dioxo-1H-benz(de)isoquinoline-2(3H)-butyric acid PHARMACOLOGICAL GROUP: Aldose reductase inhibitors Pharmacological properties: Isodibut is an inhibitor of aldose reductase enzyme. Isodibut decreases activity of aldose reductase 1.5 to 3 times and increases activity of sorbitol dehydrogenase in 1.2-1.4 times, thus inhibiting the sorbitol path of glucose metabolism (its activity is considerably increased in patients with diabetes mellitus) and prevents accumulation of sorbitol in vascular walls, nerves, and lens, inhibits the processes of protein glycosylation. The drug prevents swelling and damage of tissues, first of all vessels, nerves and lens. The drug reduces the contents of glycosylated proteins in the blood and cellular membranes. The drug improves function, metabolism, microcirculation of the brain and improves memory. The drug improves sight, blood supply of conjunctiva and retina, renal blood circulation, reduces albuminuria. Isodibut restores sensitivity in lower extremities and diminishes pain, accelerates ulcer healing, and reduces the signs of peripheral neuropathy. MEBIFONE 1.5% solution for injections INN: MEBIFONUM, ATC: L01X 22 CHEMICAL NAME: Disodium salt of methylene-bisphosphonic acid PHARMACOTHERAPEUTIC GROUP: Other antineoplastic agents Pharmacological properties: Mebiphon is a new original pharmaceutical preparation of the group of bisphosphonates, structural analogue of natural pyrophosphate. The preparation is used for patients with breast cancer and prostatic carcinoma with metastases in bones due to combination of its antitumoral and antimetastatic action. Mebiphon does not have toxic effects, which need additional treatment. The preparation improves general condition and physical activity of patients; it has a notable analgesic effect (pain in bones reduced or stopped). Mebiphon have no inhibiting effect on the system of a hemopoiesis, immunogenesis and immune response. In some patients a stimulation of hemopoiesis (both erythro- and leukopoiesis) was significant. Quantity of thrombocytes practically does not change. The diffuse changes of myocardium of variable intensity may occur in the beginning of treatment, their parameters do not vary during treatment. The tachycardia is not increased. Mebiphon has no influence on respiratory system, function of the liver and kidneys. Mebiphon reduces bone resorption and lowers the contents of serum calcium in patients with bone metastases. It alleviates a pain syndrome and decreases a risk of pathological fractures, improves a quality of life of patients with bone metastases. The types of company you would like to meetWe are interested in establishing contact with American governmental, public and private institutions, which are involved in purchases of medicines for hospitals as well as state and private companies that distribute pharmaceuticals to pharmacies trading network, as well as marketing pharmaceutical companies, pharmacy networks, etc. We are interested in development of cooperation with American pharmaceutical manufacturers for contract manufacturing and scientific researches, in and out licensing. |